Clinical Trials Directory

Trials / Sponsors / Poxel SA

Poxel SA

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnStudy to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-A
Adrenomyeloneuropathy
Phase 22023-09-01
WithdrawnStudy to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-A
ALD (Adrenoleukodystrophy)
Phase 22023-09-01
CompletedStudy to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
NASH - Nonalcoholic Steatohepatitis
Phase 12021-03-08
CompletedStudy of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic Steatohepatitis
Phase 22020-09-01
CompletedA Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
Nonalcoholic Fatty Liver
Phase 12019-08-01
CompletedA Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Nonalcoholic Fatty Liver
Phase 22019-03-29
CompletedPharmacokinetics and Metabolism of (14C)-Labelled PXL770
Healthy
Phase 12019-02-06
CompletedPharmacokinetics of Imeglimin in Hepatic Impaired Subjects
Hepatic Impairment
Phase 12018-11-06
CompletedBioequivalence of Imeglimin Tablet Formulations
Bioequivalence
Phase 12018-09-03
CompletedEffect of Cimetidine on the PK of Imeglimin
Healthy
Phase 12018-06-19
CompletedSafety, Tolerability and PK of PXL770 in Healthy Male Subjects
Metabolic Disease
Phase 12017-08-21
CompletedEffect of Imeglimin on QT/QTc Intervals in Healthy Subjects
Qt Interval, Variation in
Phase 12016-09-01
CompletedSafety, Tolerability and PK of Imeglimin in Japanese Volunteers
Type 2 Diabetes Mellitus
Phase 12015-02-01
CompletedA Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2
Type 2 Diabetes Mellitus
Phase 22013-01-01